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Cardiovascular calcification in Hispanic Americans (HA) with
chronic kidney disease (CKD) due to type 2 diabetes.
Background. Cardiovascular calcification (CVC) is common
and severe in patients with end-stage renal disease on dialysis.
However, the prevalence and severity of CVC is less well docu-
mented in patients with chronic kidney disease (CKD) not yet
on dialysis.
Methods. Fifty-eight nondialyzed HA with type 2 diabetes
and CKD were enrolled. They comprise 29 patients with stages 1
and 2 CKD (early CKD group) and 26 patients with stages 4 and
5 CKD (advanced CKD group). Coronary artery calcification
(CAC) was measured by ultrafast spiral computed tomography,
while peripheral artery calcification (PAC) was evaluated by
plain x-ray of the chest, pelvis, thighs, and lower extremities.
Results. The prevalence of CAC and PAC were significantly
higher in the advanced CKD group compared to the early CKD
group (73% vs. 38%; P < 0.01 and 85% vs. 35%; P < 0.0001,
respectively). The median CAC scores were 18-fold greater in
the advanced CKD group (138.9 vs. 7.8, respectively). By linear
regression analysis, a strong association was found between the
level of renal function and ln total volume of CAC.
Conclusion. Our data indicate that CAC and PAC are com-
mon and severe in HA diabetic patients with CKD not previ-
ously treated with dialysis, calcium-based phosphate binders, or
vitamin D analogues. Lower level of renal function is associated
with increased burden of vascular calcification in predialysis pa-
tients with CKD.
Diabetes mellitus (DM) is the most common cause of
end-stage renal disease (ESRD) in the United States and
other industrialized countries [1]. The mortality risk in
diabetic patients is 2- to 5-fold greater compared to the
general population, mainly from cardiovascular disease
(CVD) [2, 3]. Unfortunately, there is a rampant epidemic
of type 2 diabetes worldwide. This is clearly the case in
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the Hispanic American (HA) population, which also has
a 6 times higher incidence of ESRD secondary to diabetic
nephropathy (DN) compared to Caucasians [4].
Studies have shown that the mortality risk progres-
sively increases with increasing urinary albumin excre-
tion rate independent of the traditional risk factors for
CVD [5–7]. The risk is even apparent at levels well below
the currently accepted screening thresholds for a diagno-
sis of microalbuminuria [8]. Moreover, the development
of renal insufficiency also carries an increased mortality
risk independent of the traditional risk factors for CVD
[9–11].
Coronary artery calcification (CAC) is an integral part
of the atherosclerotic plaque and is an independent pre-
dictor of coronary artery disease (CAD) end points in
symptomatic and asymptomatic patients [12–14]. Recent
studies employing electron beam computed tomography
(EBCT) have shown that patients with ESRD undergo-
ing maintenance hemodialysis have high prevalence and
severity of CAC compared to age- and sex-matched nor-
mal subjects with history of CAD [15]. Of concern is
that CAC is more severe, and develops at a younger age
in dialysis patients than in the general population [15–
17]. Several dialysis-related risk factors have been impli-
cated, including dialysis vintage, high serum phosphorus,
high Ca × P product, increased intact parathyroid hor-
mone (iPTH) levels, markers of inflammation, as well as
the calcium load from use of calcium-containing phos-
phate binders [16–19].
Likewise, the incidence of peripheral artery disease
(PAD) is also high in patients with ESRD undergoing
dialysis [1]. Previous studies have shown an association
between PAD and increased mortality risk in both the
general population [20] and those with ESRD [21, 22]. Pe-
ripheral artery calcification (PAC) reflects the presence of
PAD, and has also been shown to be an independent pow-
erful predictor of future cardiovascular mortality [23]. A
recent study has demonstrated a high incidence of PAC
in dialysis patients [24].
Unlike patients on dialysis, those with chronic kidney
disease (CKD) not yet on dialysis are not exposed to some
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of the dialysis-related risk factors for CAD. Despite that,
it has been documented that a high percentage of inci-
dent dialysis patients have a substantial burden of CVD
[25, 26]. Furthermore, autopsy studies have clearly shown
that cardiovascular calcification develops in patients with
CKD before the initiation of dialysis [27–29]. What is not
clear, however, is the stage at which both CAC and PAC
begin, and their prevalence in patients with various stages
of CKD not yet on dialysis.
The purpose of the present study was 2-fold: First, to
assess the prevalence and severity of CAC and PAC in a
group of predialysis Hispanic diabetic patients with CKD,
thus excluding the impact of dialysis-related factors on
calcification, and second, to evaluate the level of calcifi-
cation in early and advanced stages of CKD.
METHODS
Patients and controls
Adult Hispanic patients (age 18–70 years) with type
2 diabetes who regularly attend the Renal and Diabetes
Clinics at the University of Texas Health Science Center
and Texas Diabetes Institute (TDI) were eligible for in-
clusion. The early CKD group included 29 patients with
type 2 diabetes and stages 1 or 2 CKD; the advanced
CKD group included 26 patients with type 2 diabetes and
stages 4 and 5 CKD. Microalbuminuria was defined as
urine albumin/creatinine ratio of >0.03 but <0.3. Exclu-
sion criteria were age greater than 70 years, non-Hispanic
ethnicity, type 1 diabetes mellitus, nondiabetic patients,
prior treatment with vitamin D or phosphate binders
such as calcium acetate, calcium carbonate, or seve-
lamer hydrochloride for more than 3 months, history of
myocardial infarction, coronary bypass grafting surgery,
and extremity amputation.
Protocol
Detailed history and physical examination was per-
formed on all subjects, with special emphasis on history
and symptoms of coronary artery disease. The study pro-
tocol was approved by the University of Texas Health
Science Center Institutional Review Board (IRB), as well
as by the University Health system IRB. All subjects gave
their written informed consent.
Laboratory assessment
All patients underwent an identical set of laboratory
studies. These included complete blood counts (CBC)
and electrolytes such as sodium, chloride, potassium, glu-
cose, bicarbonate, calcium, phosphorus, creatinine, blood
urea nitrogen (BUN), and albumin, creatinine content, as
well as the total amount of protein excreted. Glomeru-
lar filtration rate (GFR) was estimated by the Modifica-
tion of Diet in Renal Disease (MDRD) equation and
by creatinine clearance. In the early CKD group, uri-
nary microalbumin excretion was measured and microal-
bumin/creatinine ratio was obtained. The iPTH level,
plasma 25-OH vitamin D and 1,25-(OH)2 vitamin D lev-
els, lipid profile, including total serum cholesterol level,
low-density lipoprotein cholesterol (LDL), and triglyc-
eride level were also measured. All blood and urine
samples were analyzed at Quest Diagnostics, Inc. (San
Antonio, TX, USA). Electrocardiograms were obtained
in all subjects.
Radiologic assessment
Radiologic studies included plain chest x-ray and stan-
dardized plain radiographs of the hands, feet, ankles, and
pelvis in order to identify calcified vessels. Peripheral ar-
terial calcification was graded by an ordinal scale of 0 to
3, with 0 denoting absence of calcification, and 3 denoting
severe calcification [24]. The plain x-rays were read by a
radiologist who was blinded to the clinical data.
Spiral computed tomography (CT)
All subjects underwent spiral computed tomogram
studies. The procedures were performed on Siemens
SOMATOM PLUS 4 (Siemens, Forcheim, Germany) us-
ing high resolution cardiac gated CT of the coronary ar-
teries with a 100 msec scanning time and a single-slice
thickness of 3 mm. Thirty to 40 tomographic slices were
obtained for each subject during 2 breath-holding peri-
ods. Coronary calcification was analyzed using ScImage’s
(Los Angeles, CA, USA) volumetric cardiac scoring soft-
ware. A single person, blinded to the patients’ clinical
status, reviewed all spiral CT scans. A score of ≥20 was
considered evidence for abnormal CAC. Total and volu-
metric CAC scores were log (ln) transformed when an-
alyzed as a quantitative trait to reduce the problem of
non-normality. They were also analyzed as a discrete trait
(yes or no).
Statistical analysis
A cross-sectional study was carried out in which CAC
was the outcome of interest. CAC scores were log (ln)
transformed when CAC scores were analyzed as a quanti-
tative trait to reduce the problem of non-normality. CAC
was also analyzed as a discrete trait (yes or no), and CAC
score ≥20 was considered evidence for abnormal CAC.
The main exposure of interest was stage of chronic kidney
disease categorized into 2 groups; the early CKD group
included predialysis diabetic patients with stage 1 or 2
chronic kidney disease, while the advanced CKD group
included diabetic patients with stage 4 or 5 chronic kidney
disease. A second exposure of interest was PAC evaluated
by plain x-rays of the extremities as a discrete variables
and using an ordinal scale of 0 to 3. Other exposures of
interest included age, gender, duration of diabetes, BMI,
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Table 1. Baseline demographic characteristics of subjects in the early
and advanced CKD groups
Early Advanced
Variable CKD group CKD group P value
Number 29 26
Age years 51.5 56.4 0.0694
Gender (% male) 62.1 51.9 0.5897
Duration of DM years 11.6 18.0 0.0265
Body mass index 31.7 32.5 0.7740
Hypertension 72.4% 100% 0.0048
Current smoker 18.5% 4.8% 0.2115
Family history of CHD 31.0% 26.3% 0.6234
hypertension, current smoking status, family history of
coronary heart disease, as well as a series of laboratory
assays.
Baseline means and proportions, stratified by early and
advanced CKD, were calculated for various measures of
CAC [presence vs. absence, log (ln) of the CAC score
and log (ln) of the CAC volume], as well as the expo-
sures of interest. For discrete variables, Fisher exact test
was used to compare unadjusted control and study group
proportions. For continuous variables, analysis of vari-
ance (ANOVA) was used to determine age- and gender-
adjusted means stratified by control and study group.
Each exposure was modeled separately, using general
linear modes (GLM), with ln total volume of CAC as
the outcome. Age and gender were considered as covari-
ates throughout all analyses; furthermore, renal function
as measured by creatinine clearance was controlled for
when it was not the exposure of interest.
RESULTS
Characteristics of the study population
We studied a total of 55 asymptomatic Hispanic pa-
tients with type 2 diabetes mellitus who had evidence of
diabetic nephropathy. The early CKD group included 29
patients (mean age = 52 years, 62% males) with stages 1
and 2 CKD; the advanced CKD group included 26 pre-
dialysis patients (mean age = 56 years, 52% males) with
stages 4 and 5 CKD. Tables 1 and 2 list baseline demo-
graphic and laboratory characteristics of the 2 groups.
There were no differences in the age, gender, lipid pro-
file, body mass index, serum phosphorus, or family history
of CAD between the 2 groups (Table 1). However, there
were significant differences in the mean serum creatinine,
creatinine clearance, the daily urinary protein excretion,
hemoglobin, serum albumin, calcium, iPTH, vitamin D
levels, and alkaline phosphatase (Table 2). The mean du-
ration of diabetes mellitus was 11.6 and 18.0 years for
the early and advanced CKD groups, respectively (P <
0.027). The mean creatinine clearance was 78.7% and
13.1 mL/min for the early and advanced CKD groups,
respectively (P < 0.0001). The mean serum albumin lev-
Table 2. Baseline laboratory data for subjects in the early and
advanced CKD groups adjusted for age and gender
Early Advanced
Variable CKD group CKD group P value
Creatinine clearance mL/min 78.7 13.1 <0.0001
Creatinine mg/dL 0.89 5.50 <0.0001
Calcium mg/dL 9.45 8.35 <0.0001
Phosphorus mg/dL 4.42 5.05 0.4455
Albumin g/dL 4.18 3.52 <0.0001
Alkaline phosphatase 82 103 0.0107
Hemoglobin g/dL 13.8 10.7 <0.0001
24-hour urine protein mg 334 5172 0.0017
Total cholesterol 184 196 0.3244
LDL cholesterol mg/dL 100 118 0.2238
HDL 45 47 0.6128
Triglycerides 214 203 0.8019
25 OH Vitamin D ng/mL 44.0 27.1 <0.0001
1,25(OH)2 Vitamin D ng/mL 21.0 10.3 <0.0001
iPTH pg/mL 32.6 285 <0.0001
Table 3. Prevalence and age- and sex-adjusted means of CAC and
PAC in the early and advanced CKD groups
Early Advanced
Variablea CKD group CKD group P value
CAC 37.9% 73.1% 0.0144
PACS (yes vs. no) 34.5% 85.2% 0.0001
ln total volume of CAC 2.80 4.46 0.0107
ln total score of CAC 2.80 4.52 0.0116
Score of PAC 0.54 1.79 <0.0001
aln, log transformed value. Fisher exact test was used to assess group differences.
els were 4.2 versus 3.5 g/dL in the early and advanced
CKD groups, respectively (P 0.0001). The mean 25 OH
D3 was 44.0 versus 27.1 ng/mL in the early and advanced
CKD groups (P < 0.0001); the mean 1, 25(OH)2D3 was
21.0 versus 10.3 ng/mL in the 2 groups, respectively (P <
0.0001). Patients in the advanced CKD group had signifi-
cantly higher prevalence of hypertension (100% vs. 72%,
P = 0.0048).
Coronary artery calcification
After adjustment for age and sex, coronary artery cal-
cification was present in 38% and 73% of patients in early
and advanced groups, respectively (P = 0.0144) (Table 3;
Fig. 1). The unadjusted distribution of CAC scores in the
2 groups is shown in Figure 2. The median CAC scores
were 7.8 and 138.9 in the early and advanced CKD groups,
respectively. Thus, the median CAC scores were 18 times
higher in the advanced CKD group than in the early CKD
group. In the early CKD group, 59% of patients had no
CAC scores, while only 27% of the patients in the ad-
vanced CKD group had no CAC scores. Moreover, only
7% of patients in the early CKD group had CAC scores
greater than 400 compared to 39% of patients in the ad-
vanced CKD group. Finally, using separate general linear
regression models for each exposure with ln total volume
of CAC as the outcome, the level of renal function, as
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Fig. 1. Prevalence of coronary artery calcification and peripheral
artery calcification in the early (open bars) and advanced (solid bars)
CKD groups adjusted for age and sex. Compared with the early CKD
group, the advanced CKD group had a significantly higher prevalence
of CAC (73% vs. 38%, P < 0.01) and PAC (85% vs. 35%, P < 0.0001).
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Fig. 2. Unadjusted distribution of coronary artery calcification scores
in the early (open bars) and advanced (solid bars) CKD groups. Only
7% of patients in the early CKD group had CAC scores greater than 400
compared to 39% of patients in the advanced CKD group. In the early
CKD group, 59% of patients had no CAC, while only 27% of the patients
in the advanced CKD group had no CAC. Age- and gender-adjusted
log-transformed CAC scores were significantly higher in advanced CKD
group patients than in early CKD group (4.52 vs. 2.80, P = 0.0116) (Table
3).
well as smoking status, was found to be strongly associ-
ated with CAC (Table 4).
Peripheral artery calcification
After adjustment for age and sex, PAC was present in
35% and 85% of patients in early and advanced CKD
groups, respectively (P = 0.0001) (Table 3; Fig. 1). The
median number of sites with PAC was 0 and 4 in the early
and advanced CKD groups, respectively. Moreover, the
PAC was more severe in the advanced CKD group. The
median PAC score was 0 and 2 in the early and advanced
CKD groups, respectively. While 19 patients (66%) in
the early group had no evidence of PAC in any of the
Table 4. Associationa between exposures and ln CAC volume
adjusted for age, gender, and renal function as estimated by creatinine
clearance
Exposure P value
Creatinine clearanceb mL/min 0.0092
Hypertension (yes vs. no) 0.3184
Smoking status (yes vs. no) 0.0249
Family history of CHD (yes vs. no) 0.0741
Score of PAC 0.0690
HDL mg/dL 0.3077
LDL mg/dL 0.9220
Triglycerides mg/dL 0.9786
Serum calcium mg/dL 0.6117
Serum phosphorus mg/dL 0.2268
aSeparate general linear regression models were used for each exposure with
the outcome of ln CAC volume.
bAdjusted for age and gender.
investigated sites, only 3 (11%) in the advanced CKD
group did not have PAC.
In general, PAC involved more vessels and was more
severe in patients with higher CAC scores. Of the 19 pa-
tients in the early CKD group who had no PAC, 11 had
CAC, while among the 11 without CAC, 3 had PAC. By
contrast, of the 3 patients in the advanced CKD group
who had no PAC, only 1 did not also have CAC, while in
the 3 without CAC, 2 had PAC.
DISCUSSION
This study clearly shows that CAC and PAC are preva-
lent in diabetic patients with CKD prior to treatment
with dialysis, calcium-containing phosphate binders, or
vitamin D. Moreover, the prevalence and severity of cal-
cification in these patients were found to increase with
the level of CKD. Patients with stages 4 and 5 CKD had
at least 2-fold higher prevalence of CAC and PAC com-
pared to those with stages 1 and 2 CKD. Coronary artery
calcification scores ≥20 were present in 73% and 38%
of patients in advanced and early CKD groups, respec-
tively (P = 0.0144) (Table 3), while PAC was present in
85% and 35% of patients in the 2 groups, respectively
(P = 0.0001). Moreover, age- and gender-adjusted log-
transformed CAC scores were significantly higher in ad-
vanced group than in early CKD group (4.52 vs. 2.80,
P = 0.0116) (Table 3). Finally, linear regression analysis
revealed a strong association between the level of renal
function and smoking, with ln total volume of CAC as the
outcome (Table 4).
The risk of CVD in patients with chronic renal fail-
ure is far greater than in the general population. The
prevalence of coronary artery disease in patients with
ESRD receiving chronic dialysis is approximately 40%
[25]. Moreover, cardiovascular mortality in these patients
has been estimated to be approximately 9% per year, 10
to 20 times higher than in the general population [25].
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Diabetes mellitus is the most common cause of ESRD in
the United States, and is a recognized major cardiovascu-
lar risk factor due to accelerated atherosclerosis. Cardio-
vascular disease morbidity and mortality, as well as CAC,
are known to be higher in patients with diabetes than in
those without diabetes.
Unfortunately, the prevalence of CVD is underesti-
mated in both the general population and in patients
with renal disease. Approximately 50% of myocardial in-
farctions occur in patients with no prior history of heart
disease. Of greater concern is the development of silent
myocardial infarction in diabetic subjects. Coronary
artery calcium deposition is an integral part of the
atherosclerotic plaque, and calcium scores obtained by
electron beam computed tomography (EBCT) corre-
late with histologic, intravascular ultrasound, and angio-
graphic measurements of CAD [30, 31]. Moreover, the
coronary artery calcium score is an independent predic-
tor of subsequent cardiac events in both symptomatic
and asymptomatic individuals. Patients with ESRD on
dialysis have increased incidence and greater quantity
of coronary artery calcium. Several studies have shown
that the prevalence of CAC, as well as valvular calcifi-
cation, is increased in patients with ESRD on mainte-
nance dialysis [15–19]. Although these studies were not
limited to diabetic patients, it is likely that additive effects
of traditional risk factors for atherosclerosis and dialysis-
related risk factors played a role. Nonetheless, these stud-
ies have implicated dialysis and the use of calcium-based
phosphate binders in the high prevalence and severity
of CAC in dialysis patients. Interestingly, the high preva-
lence of CAC in our patients with stages 4 and 5 CKD who
have never been dialyzed was similar to that reported
by these investigators in dialysis patients, although the
later studies were not limited to patients with diabetes
[15, 16, 19]. Nevertheless, our results clearly represent
strong evidence that CAC not only starts early in the
course of CKD, but that worsening levels of renal func-
tion are associated with increased levels of vascular cal-
cification. Moreover, the high prevalence and extent of
CAC and PAC in our patients were not correlated with
the serum calcium or phosphorus levels, suggesting that
other uremia-related factors may play a major role in the
pathogenesis of vascular calcification.
Previous clinical and autopsy studies have also docu-
mented increased prevalence of CAC in predialysis CKD
patients [28, 29, 32]. In 1976, Meema et al reported that
arterial calcification developed in 38% of patients with
creatinine clearance less than 20 mL/minute who had not
been previously dialyzed, 43% in those beginning dialy-
sis, and 44% among dialysis patients [28]. In an autopsy
study of 56 dialyzed and 18 nondialyzed patients with
chronic renal failure, Kuzela et al found calcification in
79% of dialyzed patients and 44% in the nondialyzed pa-
tients [29]. More recently, Merjanian et al, who studied
a group of nondialyzed subjects with diabetic CKD sim-
ilar to ours, demonstrated a high prevalence of coronary
and valvular calcification among their patients. They also
showed that calcification was often severe long before the
disease progresses to ESRD [33].
This study documents that CAC and PAC in our dia-
betic patients with various stages of CKD begin in the
early stages of renal disease, and appear to increase with
worse level of renal function. While only 2 patients (7%)
in the early CKD group had CAC scores greater than 400,
a level known to correlate with significant cardiac events,
10 patients (39%) in the advanced CKD group had se-
vere CAC. The results also show that extensive CAC,
similar to that reported in dialysis patients, also occurs in
predialysis patients. CAC scores greater than 1000 were
seen in 27% of our advanced CKD patients (Fig. 2). In-
terestingly, some patients did not have CAC despite the
presence of diabetes as well as advanced renal failure,
suggesting that these patients may be protected from the
development of CAC. However, even among this group,
the impact of lower renal function was evident as more
patients in the early CKD group were without evidence
of CAC than in the advanced CKD group (59% vs. 27%)
(Fig. 2).
Our study differs from that of Merjanian et al, who also
studied subjects with type 2 diabetes [33]. First, while they
retrospectively analyzed their data on EBCT scans, our
scans were prospectively performed on all patients. Sec-
ond, they compared the prevalence and extent of CAC
scores in their diabetic patients with relatively well pre-
served renal function to that of diabetic patients with
normal renal function; we compared these parameters in
patients with early and advanced diabetic CKD. Third, in
their study, there was no significant correlation between
any measure of renal function and either the prevalence
or severity of CAC, while in our study, such a correlation
was clearly found. Undoubtedly, renal disease plays a role
in predisposition to CAD. It has been previously shown
that the development of renal insufficiency carries an in-
creased mortality risk independent of the traditional risk
factors for CVD [9–11]. Therefore, it is not surprising that
in our study, the CAC scores were higher in those with
stages 4 and 5 CKD compared to those with stages 1 and
2 CKD.
The pathogenesis of CAC and PAC in patients with
CKD is still being investigated. Besides diabetes, tradi-
tional risk factors including male gender, older age, smok-
ing, hypertension, anemia, proteinuria, oxidative stress,
chronic inflammation, malnutrition, and elevated homo-
cysteine level have been implicated in the accelerated
atherosclerosis seen in patients with renal disease, includ-
ing diabetic nephropathy. The relationship between the
degree of proteinuria and CAC has been carefully stud-
ied by several groups. Yoshida et al reported a progres-
sive increase in the CAC score, with increasing degree
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of proteinuria among patients with type 2 diabetes [34].
Wagenknecht et al also reported a significant correlation
between age-adjusted CAC score and albumin/creatinine
ratio [35]. Furthermore, calcification in other vascular
beds has also been reported to correlate with increas-
ing proteinuria in patients with type 2 diabetes [36–38].
Finally, severe coronary and valvular calcification was re-
cently documented in nondialyzed patients with type 2
diabetes and renal disease long before the disease pro-
gressed to ESRD [33].
There are a number of possible explanations for the
increased risk of CVD and cardiovascular calcification in
patients with CKD [39, 40]. First, both proteinuria and
reduced renal function are associated with known tradi-
tional cardiovascular risk factors, such as dyslipidemia
and hypercoagulability [6–8]. Hyperlipidemia, particu-
larly increased low-density lipoproteins (LDL), has been
implicated in progression of CAC. Clinical studies have
shown that serum levels of LDL cholesterol are directly
related to the prevalence and extent of CAC as measured
by computed tomography, while levels of high-density
lipoprotein (HDL) cholesterol were inversely related [41,
42]. Moreover, the effect of lowering the LDL choles-
terol levels on progression of calcification was reported
by several groups [43, 44]. Surprisingly, we did not find
any association between LDL level and CAC or PAC.
The reason for this is unclear but may be related to our
somewhat small sample size, which may have limited our
ability to demonstrate a significant correlation between
LDL level and vascular calcification. Other investigators
also reported lack of association between lipid parame-
ters and measures of vascular calcification [33]. Second,
both may be markers of diffuse endothelial dysfunction
or markers for the severity of known vascular disease,
such as hypertension or diabetes [45–46]. Third, they may
be associated with markers of inflammation, such as C-
reactive protein (CRP) [47]. Clearly, these same factors
are known to be associated with increased prevalence
of cardiovascular calcification and may explain the high
prevalence of CAC and PAC in our patients, as well as
in similar patients in other studies. Finally, in addition to
CKD we believe that diabetes may have contributed to
the high prevalence and severity of calcification.
CONCLUSION
CAC as well as PAC are common in diabetic pa-
tients with CKD not yet on dialysis. Vascular calcification
clearly develops early in the course of CKD, and higher
degrees of calcification are associated with lower levels
of renal function. The level of renal function seems to
be a major determinant of the prevalence and severity of
arterial calcification in these patients.
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